Skip to main content
Top
Published in: Rheumatology International 4/2015

01-04-2015 | Original Article - Validation Studies

Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire

Authors: Jeanette Wilburn, Stephen P. McKenna, James Twiss, Matthew Rouse, Mariusz Korkosz, Roman Jancovic, Petr Nemec, César Francisco Pacheco-Tena, Alain Saraux, Rene Westhovens, Patrick Durez, Mona Martin, Marika Tammaru

Published in: Rheumatology International | Issue 4/2015

Login to get access

Abstract

The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire was developed directly from rheumatoid arthritis (RA) patients in the United Kingdom and the Netherlands to measure quality of life (QoL). Since then, it has become widely used in clinical studies and trials and has been adapted for use in 24 languages. The objective was to develop and validate 11 additional language versions of the RAQoL in US English, Mexican Spanish, Argentinean Spanish, Belgian French, Belgian Flemish, French, Romanian, Czech, Slovakian, Polish and Russian. The language adaptation and validation required three stages: translation, cognitive debriefing interviews and validation survey. The translation process involved a dual-panel methodology (bilingual panel followed by a lay panel). The validation survey tested the psychometric properties of the new scales and included either the Nottingham Health Profile (NHP) or the Health Assessment Questionnaire (HAQ) as comparators. Internal consistency of the new language versions ranged from 0.90 to 0.97 and test–retest reliability from 0.85 to 0.99. RAQoL scores correlated as expected with the HAQ. Correlations with NHP sections were as expected: highest with energy level, pain and physical mobility and lowest with emotional reactions, sleep disturbance, and social isolation. The adaptations exhibited construct validity in their ability to distinguish subgroups of RA patients varying by perceived disease severity and general health. The new language versions of the RAQoL meet the high psychometric standards of the original UK English version. The new adaptations represent valid and reliable tools for measuring QoL in international clinical trials involving RA patients.
Literature
1.
go back to reference Whalley D, McKenna SP, De Jong Z, Van Der Heijde D (1997) Quality of life in rheumatoid arthritis. J Rheumatol 36:884–888CrossRef Whalley D, McKenna SP, De Jong Z, Van Der Heijde D (1997) Quality of life in rheumatoid arthritis. J Rheumatol 36:884–888CrossRef
3.
go back to reference National Institute for Health and Care Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. CG79. National Institute for Health and Care Excellence, London National Institute for Health and Care Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. CG79. National Institute for Health and Care Excellence, London
4.
go back to reference Pollard L, Choy EH, Scott DL (2005) The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 23:S43–S52PubMed Pollard L, Choy EH, Scott DL (2005) The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 23:S43–S52PubMed
5.
go back to reference Hunt SM, McKenna SP (1992) The QLDS: a scale for the measurement of quality of life in depression. Health Policy 22:307–319CrossRefPubMed Hunt SM, McKenna SP (1992) The QLDS: a scale for the measurement of quality of life in depression. Health Policy 22:307–319CrossRefPubMed
6.
go back to reference Cox SR, McWilliams L, Massy-Westropp N, Meads DM, McKenna SP, Proudman S (2007) Adaptation of the RAQoL for use in Australia. Rheumatol Int 27:661–666CrossRefPubMed Cox SR, McWilliams L, Massy-Westropp N, Meads DM, McKenna SP, Proudman S (2007) Adaptation of the RAQoL for use in Australia. Rheumatol Int 27:661–666CrossRefPubMed
7.
go back to reference Hedin PJ, McKenna SP, Meads DM (2006) The rheumatoid arthritis quality of life (RAQoL) for Sweden: adaptation and validation. Scand J Rheumatol 35:117–123CrossRefPubMed Hedin PJ, McKenna SP, Meads DM (2006) The rheumatoid arthritis quality of life (RAQoL) for Sweden: adaptation and validation. Scand J Rheumatol 35:117–123CrossRefPubMed
8.
go back to reference Thorsen H, Hansen TM, McKenna SP, Sørensen SF, Whalley D (2001) Adaptation into Danish of the stanford health assessment questionnaire (HAQ) and the rheumatoid arthritis quality of life scale (RAQoL). Scand J Rheumatol 30:103–109CrossRefPubMed Thorsen H, Hansen TM, McKenna SP, Sørensen SF, Whalley D (2001) Adaptation into Danish of the stanford health assessment questionnaire (HAQ) and the rheumatoid arthritis quality of life scale (RAQoL). Scand J Rheumatol 30:103–109CrossRefPubMed
9.
go back to reference Neville C, Whalley D, McKenna S, Le Comte M, Fortin PR (2001) Adaptation and validation of the rheumatoid arthritis quality of life scale for use in Canada. J Rheumatol 28:1505–1510PubMed Neville C, Whalley D, McKenna S, Le Comte M, Fortin PR (2001) Adaptation and validation of the rheumatoid arthritis quality of life scale for use in Canada. J Rheumatol 28:1505–1510PubMed
10.
go back to reference Dougados M, Kissel K, Sheeran T et al (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72:43–50CrossRefPubMedCentralPubMed Dougados M, Kissel K, Sheeran T et al (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72:43–50CrossRefPubMedCentralPubMed
11.
go back to reference Inotai A, Rojkovich B, Fulop A, Jaszay E, Agh T, Meszaros A (2012) Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int 32:963–969CrossRefPubMed Inotai A, Rojkovich B, Fulop A, Jaszay E, Agh T, Meszaros A (2012) Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int 32:963–969CrossRefPubMed
12.
go back to reference Nam JL, Villeneuve E, Hensor EMA et al (2013) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 0:1–11 Nam JL, Villeneuve E, Hensor EMA et al (2013) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 0:1–11
13.
go back to reference Keystone EC, Wang MM, Layton M, Hollis S, McInees IB (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 7:1630–1635CrossRef Keystone EC, Wang MM, Layton M, Hollis S, McInees IB (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 7:1630–1635CrossRef
14.
go back to reference Herenuis MM, Hoving JL, Sluiter JK et al (2010) Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. J Occup Environ Med 52:618–622CrossRef Herenuis MM, Hoving JL, Sluiter JK et al (2010) Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. J Occup Environ Med 52:618–622CrossRef
15.
go back to reference Taha NM, Ali ZH (2011) Effect of reflexology on pain and quality of life in a patient with rheumatoid arthritis. Life Sci J 8:357–365 Taha NM, Ali ZH (2011) Effect of reflexology on pain and quality of life in a patient with rheumatoid arthritis. Life Sci J 8:357–365
16.
go back to reference De Jong Z, Van Der Heijde D, McKenna SP, Whalley D (1997) The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 36:878–883CrossRefPubMed De Jong Z, Van Der Heijde D, McKenna SP, Whalley D (1997) The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 36:878–883CrossRefPubMed
17.
go back to reference Hunt SM, Alonso J, Bucquet D, Niero M, Wiklund I, McKenna S (1991) Cross-cultural adaptation of health measures. European group for health management and quality of life assessment. Health Policy 19:33–44CrossRefPubMed Hunt SM, Alonso J, Bucquet D, Niero M, Wiklund I, McKenna S (1991) Cross-cultural adaptation of health measures. European group for health management and quality of life assessment. Health Policy 19:33–44CrossRefPubMed
18.
go back to reference Hagell P, Hedin PJ, Meads DM, Nyberg L, McKenna SP (2010) Effects of method of translation of patient-reported health outcome questionnaires: a randomized study of the translation of the rheumatoid arthritis quality of life (RAQoL) instrument for Sweden. Value Health 13:424–430CrossRefPubMed Hagell P, Hedin PJ, Meads DM, Nyberg L, McKenna SP (2010) Effects of method of translation of patient-reported health outcome questionnaires: a randomized study of the translation of the rheumatoid arthritis quality of life (RAQoL) instrument for Sweden. Value Health 13:424–430CrossRefPubMed
19.
go back to reference Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145CrossRefPubMed Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145CrossRefPubMed
20.
go back to reference Hunt SM, McEwen J, McKenna SP (1986) Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 35:185–188 Hunt SM, McEwen J, McKenna SP (1986) Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 35:185–188
21.
go back to reference Weiner EA, Stewart BJ (1984) Assessing individuals. Little Brown, Boston Weiner EA, Stewart BJ (1984) Assessing individuals. Little Brown, Boston
22.
go back to reference Ware JE Jr, Shelbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483CrossRefPubMed Ware JE Jr, Shelbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483CrossRefPubMed
23.
go back to reference Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamovicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH (2005) Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 14:1333–1344CrossRefPubMed Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamovicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH (2005) Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 14:1333–1344CrossRefPubMed
24.
go back to reference Angst F, Verra ML, Lehmann S, Aeschlimann A (2008) Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain. BMC Med Res Methodol 25:26CrossRef Angst F, Verra ML, Lehmann S, Aeschlimann A (2008) Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain. BMC Med Res Methodol 25:26CrossRef
25.
go back to reference Jull A, Paraq V, Walker N, Rodgers A (2010) Responsiveness of generic and disease-specific health-related quality of life instruments to venous ulcer healing. Wound Repair Regen 18:26–30CrossRefPubMed Jull A, Paraq V, Walker N, Rodgers A (2010) Responsiveness of generic and disease-specific health-related quality of life instruments to venous ulcer healing. Wound Repair Regen 18:26–30CrossRefPubMed
26.
go back to reference Hunt SM, Alonso J, Bucquet D, Niero M, Wiklund I, McKenna S (1991) Cross-cultural adaptations of health measures. European group for health management and quality of life assessment. Health Policy 19:33–44CrossRefPubMed Hunt SM, Alonso J, Bucquet D, Niero M, Wiklund I, McKenna S (1991) Cross-cultural adaptations of health measures. European group for health management and quality of life assessment. Health Policy 19:33–44CrossRefPubMed
27.
go back to reference Linacre JM (1994) Sample size and item calibration stability. Rasch Meas Trans 7:328 Linacre JM (1994) Sample size and item calibration stability. Rasch Meas Trans 7:328
28.
go back to reference Kutlay S, Küçükdeveci AA, Gönül D, Tennant A (2003) Adaptation and validation of the Turkish version of the rheumatoid arthritis quality of life scale. Rheumatol Int 23:21–26PubMed Kutlay S, Küçükdeveci AA, Gönül D, Tennant A (2003) Adaptation and validation of the Turkish version of the rheumatoid arthritis quality of life scale. Rheumatol Int 23:21–26PubMed
Metadata
Title
Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire
Authors
Jeanette Wilburn
Stephen P. McKenna
James Twiss
Matthew Rouse
Mariusz Korkosz
Roman Jancovic
Petr Nemec
César Francisco Pacheco-Tena
Alain Saraux
Rene Westhovens
Patrick Durez
Mona Martin
Marika Tammaru
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 4/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3138-4

Other articles of this Issue 4/2015

Rheumatology International 4/2015 Go to the issue

Review Article - Educational Review

Musculoskeletal problems in pregnancy

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.